Farnesyltransferase inhibitors: An overview of the results of preclinical and clinical investigations

Cancer Research

Volumn 63, Issue 18, 2003, Pages 5656-5668

  Brunner, Thomas B ^a   Hahn, Stephen M ^a   Gupta, Anjali K ^a   Muschel, Ruth J ^a   McKenna, W Gillies ^a   Bernhard, Eric J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IRINOTECAN; L 778123; LONAFARNIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; TOPOTECAN;

ABDOMINAL WALL HERNIA; ACUTE KIDNEY FAILURE; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TARGETING; DYSPNEA; FATIGUE; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION; LEUKOPENIA; LUNG EMBOLISM; MONOTHERAPY; MULTICENTER STUDY; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHOTOPHOBIA; PNEUMONIA; PRIORITY JOURNAL; RADIOSENSITIVITY; RASH; REVIEW; SEPSIS; SOMNOLENCE; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; XEROSTOMIA;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS;

EID: 0141842714     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (149)

1. Maurer-Stroh, S., Washietl, S., and Eisenhaber, F. Protein prenyltransferases. Genome Biol., 4: 212.1-212.9, 2003.
2. Chen, W. J., Andres, D. A., Goldstein, J. L., Russell, D. W., and Brown, M. S. cDNA cloning and expression of the peptide-binding β subunit of rat p21ras farnesyltransferase, the counterpart of yeast DPR1/RAM1. Cell, 66: 327-334, 1991.
3. Lebowitz, P. F., Casey, P. J., Prendergast, G. C., and Thissen, J. A. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J. Biol. Chem., 272: 15591-15594, 1997.
4. Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., and Pai, J. K. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem., 272: 14459-14464, 1997.
5. Rowell, C. A., Kowalczyk, J. J., Lewis, M. D., and Garcia, A. M. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem., 272: 14093-14097, 1997.
6. Zhang, F. L., Kirschmeier, P., Carr, D., James, L., Bond, R. W., Wang, L., Patton, R., Windsor, W. T., Syto, R., Zhang, R., and Bishop, W. R. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J. Biol. Chem., 272: 10232-13239, 1997.
7. Sun, J., Qian, Y., Hamilton, A. D., and Sebti, S. M. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-ras prenylation but each alone is sufficient to supress human tumor growth in nude mouse xenografts. Oncogene, 16: 1467-1473, 1998.
8. Tamanoi, F. Inhibitors of Ras farnesyltransferases. Trends Biochem. Sci., 18: 349-353, 1993.
9. Sebti, S. M., and Hamilton, A. D. Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs. Biochem. Soc. Trans., 24: 692-699, 1996.
10. Cox, A. D., and Der, C. J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta, 1333: F51-F71, 1997.
11. Gelb, M. H., Scholten, J. D., and Sebolt-Leopold, J. S. Protein prenylation: from discovery to prospects for cancer treatment. Curr. Opin. Chem. Biol., 2: 40-48, 1998.
12. Kohl, N. E. Farnesyltransferase inhibitors. Preclinical development. Ann. N. Y. Acad. Sci., 886: 91-102, 1999.
13. Sebti, S. M., and Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Oncogene, 9: 2767-2782, 2000.
14. Hancock, J. F., Paterson, H., and Marshall, C. J. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell, 63: 133-139, 1990.
15. Leonard, D. M. Ras farnesyltransferase: a new therapeutic target. J. Med. Chem., 40: 2971-2990, 1997.
16. Manne, V., Yan, N., Carboni, J. M., Tuomari, A. V., Ricca, C. S., Brown, J. G., Andahazy, M. L., Schmidt, R. J., Patel, D., and Zahler, R. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene. 10: 1763-1779, 1995.
17. Wang, Y., and You, M. Alternative splicing of the K-ras gene in mouse tissues and cell lines. Exp. Lung Res., 27: 255-267, 2001.
18. Koera, K., Nakamura, K., Nakao, K., Miyoshi, J., Toyoshima, K., Hatta, T., Otani, H., Alba, A., and Katsuki, M. K-ras is essential for the development of the mouse embryo. Oncogene, 15: 1151-1159, 1997.
19. Johnson, L., Greenbaum, D., Cichowski, K., Mercer, K., Murphy, E., Schmitt, E., Bronson, R. T., Umanoff, H., Edelmann, W., Kucherlapati, R., and Jacks, T. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev., 11: 2468-2481, 1997.
20. Umanoff, H., Edelmann, W., Pellicer, A., and Kucherlapati, R. The murine N-ras gene is not essential for growth and development. Proc. Natl. Acad. Sci. USA, 92: 1709-1713, 1995.
21. Esteban, L. M., Vicario-Abejon, C., Fernandez-Salguero, P., Fernandez-Medarde A., Swaminathan, N., Yienger, K., Lopez, E., Malumbres, M., McKay, R., Ward, J. M., Pellicer, A., and Santos, E. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Cell Biol., 21: 1444-1452, 2001.
22. Willumsen, B. M., Christensen, A., Hubbert, N. L., Papageorge, A. G., and Lowy, D. R. The p21 ras C-terminus is required for transformation and membrane association. Nature (Lond.), 310: 583-586, 1984.
23. ras is two-step and involves carboxyl-methylation and carboxyterminal proteolysis. EMBO J., 8: 1093-1098, 1989.
24. Hancock, J. F., Cadwallader, K. and Marshall, C. J. Methylation and proteolysis are essential for efficient membrane binding of prenylated p21 K-ras(B). EMBO J., 10: 641-646, 1991.
25. Prior, I. A., and Hancock, J. F. Compartmentalization of Ras proteins. J. Cell Sci., 114: 1603-1608, 2001.
26. Jaumot, M., Yan, J., Clyde-Smith, J., Sluimer, J., and Hancock, J. F. The linker domain of the Ha-Ras hypervariable region regulates interactions with exchange factors, Raf-1 and phosphoinositide 3-kinase. J. Biol. Chem., 277: 272-278, 2002.
27. Chiu, V. K., Bivona, T., Hach, A., Sajous, J. B., Silletti, J., Wiener, H., Johnson, R. L., Cox, A. D., and Philips, M. R. Ras signalling on the endoplasmic reticulum and the Golgi. Nat. Cell Biol., 4: 343-350, 2002.
28. Willumsen, B. M., Norris, K., Papageorge, A. G., Hubbert, N. L., and Lowy, D. R. Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J., 3: 2581-2585, 1984.
29. Jackson, J. H., Cockran, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., and Der, C. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci USA, 87: 3042-3046, 1990.
30. Buss, J. E., Solski, P. A., Schaeffer, J. P., MacDonald, M. J., and Der, C. J. Activation of the cellular proto-oncogene product p21ras by addition of a myristylation signal. Science (Wash. DC), 243: 1600-1602, 1989.
31. Pruitt, K., and Der, C. J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett., 171: 1-10, 2001.
32. Kim, K., Lindstrom, M. J., and Gould, M. N. Regions of h- and k-ras that provide organ specificity/potency in mammary cancer induction. Cancer Res. 62, 1241-1245, 2002.
33. Hagemann, C., and Blank, J. L. The ups and downs of MEK kinase interactions. Cell Signal., 13: 863-875. 2001.
34. Carpenter, C. L., and Cantley, L. C. Phosphoinositide kinases. Curr. Opin. Cell Biol., 8: 153-158, 1996.
35. Nicholson, K. M., and Anderson, N. G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal., 14: 381-395, 2002.
36. Wolthuis, R. M., and Bos, J. L. Ras caught in another affair: the exchange factors for Ral. Curr. Opin. Genet. Dev., 9: 112-117, 1999.
37. Reuther, G. W., and Der, C. J. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr. Opin. Cell Biol., 12: 157-165, 2000.
38. Urano, T., Emkey, R., and Feig, L. A. Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. EMBO J., 15: 810-816, 1996.
39. Aguirre-Ghiso, J. A., Frankel, P., Farias, E. F., Lu. Z., Jiang, H., Olsen, A., Feig, L. A., de Kier Joffe, E. B., and Foster, D. A. Rala requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metal loproteases. Oncogene, 18: 4718-4725, 1999.
40. White, M. A., Vale, T., Camonis, J. H., Schaefer, E., and Wigler, M. H. A role for the Ral guanine nucleotide dissociation stimulator in mediating Ras-induced transformation. J. Biol. Chem., 271: 16439-16442, 1996.
41. Khosravi-Far, R., White, M. A., Westwick, J. K., Solski, P. A., Chrzanowska-Wodnicka, M., Van Aelst, L., Wigler, M. H., and Der, C. J. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol. Cell Biol., 16: 3923-3933, 1996.
42. Webb, C. P., Van Aelst, L., Wigler, M. H., and Woude, G. F. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc. Natl. Acad. Sci. USA, 95: 8773-8778, 1998.
43. Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Orliff, A., and Gibbs, J. B. Selective inhibition of ras dependent transformation by a farnesyltransferase inhibitor. Science (Wash. DC), 260: 1934-1936, 1993.
44. Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M. D., and Garcia, A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res., 55: 5310-5314, 1995.
45. Sepp-Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, J. B., Oliff, A., and Rosen, N. A peptidomimetic inhibitor of Farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res., 55: 5302-5309, 1995.
46. End, D. W., Smets, G., Todd, A. V., Applegate, T. L., Fuery, C. J., Angibaud, P., Venet, M., Sanz, G., Poignet, H., Skrzat, S., Devine, A., Wouters, W., and Bowden, C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res., 61: 131-137, 2001.
47. Prevost, G. P., Pradines, A., Brezak, M. C., Lonchampt, M. O., Viossat, I., Ader, I., Toulas, C., Kasprzyk, P., Gordon, T., Favre, G., and Morgan, B. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase. BIM-46228. Int. J. Cancer. 91: 718-722, 2001.
48. Lebowitz, P. F., Sakamuro, D., and Prendergast, G. C. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res., 57: 708-713, 1997.
49. Pollack, I. F., Bredel, M., Erff, M., Hamilton, A. D., and Sebti, S. M. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth. II. Preclinical studies in a nude mouse model. Neurosurgery, 45: 1208-1214, 1999.
50. 1 block in p53 wild type tumor cells. J. Biol. Chem., 273: 20243-20251, 1998.
51. Sirotnak, F. M., Sepp-Lorenzino, L., Kohl, N. E., Rosen, N., and Scher, H. I. A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility. Cancer Chemother. Pharmacol. 46: 79-83, 2000.
52. Omer, C. A., Chen, Z., Diehl, R. E., Conner, M. W., Chen, H. Y., Trumbauer, M. E., Gopal-Truter, S., Seeburger, G., Bhimnathwala, H., Abrams, M. T., Davide, I. P., Ellis, M. S., Gibbs, J. B., Greenberg, I., Koblan, K. S., Kral, A. M., Liu, D., Lcbell, R. B., Miller, P. J., Mosser, S. D., O'Neill, T. J., Rands, E., Schaber, M. D., Senderak, E. T., Oliff, A., and Kohl, N. E. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res., 60: 2680-2688, 2000.
53. Kohl, N., Omer, C., Conner, M., Anthony, N., Davide, J., Desolms, S., Giuliani, E., Gomez, R., Graham, S., Hamilton, K., Handt, L., Hartman, G., Koblan, K., Kral, K., Miller, P., Mosser, S., O'Neill, T., Rands, E., Schaber, M., Gibbs, J., and Oliff, A. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med., 1: 792-797, 1995.
54. Rak, J., Mitsubashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., and Kerbel, R. S. Mutant ras oncogenes up-regulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res., 55: 4575-4580, 1995.
55. Sheibani, N., and Frazier, W. A. Repression of thrombospondin-1 expression a natural inhibitor of angiogenesis, in polyoma middle T transformed N1H3T3 cells. Cancer Lett., 107: 45-52, 1996.
56. Cohen-Jonathan, E., Evans, S. M., Koch, C. J., Muschel, R. J., McKenna, W. G., Wu, J., and Bernhard, E. J. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res., 61: 2289-2293, 2001.
57. Feldkamp, M. M., Lau, N., and Guha, A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene, 18: 7514-7526, 1999.
58. Gu, W. Z., Tahir, S. K., Wang, Y. C., Zhang, H. C., Cherian, S. P., O'Connor, S., Leal, J. A., Rosenberg, S. H., and Ng, S. C. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. Eur. J. Cancer, 35: 1394-1401, 1999.
59. deSolms, S. J., Deana, A. A., Giuliani, E. A., Graham, S. L., Kohl, N. E., Mosser, S. D., Oliff, A. I., Pompliano, D. L., Rands, E., Scholz, T. H., et al. Pseudodipeptide inhibitors of protein farnesyltransferase. J. Med. Chem., 38: 3967-3971, 1995.
60. Lobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H. G., Brucker, M. J., Buser, C. A., Davide, J. P., deSolms, S. J., Dinsmore, C. J., Ellis-Hutchings, M. S., Kral, A. M., Liu, D., Lumma, W. C., Machotka, S. V., Rands, E., Williams, T. M., Graham, S. L., Hartman, G. D., Oliff, A. I., Heimbrook, D. C., and Kohl, N. E. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res., 61: 8758-8768, 2001.
61. Hahn, S., Bernhard, E., Kiel, K., Morrison, B., Mohiuddin, M., Delaney, T. F., Smith, D., Brown, R., Pramanik, B., Deutsch, P., Muschel, R., and McKenna, W. Preclinical and Phase I trial results of the FFI L-778,123 and radiotherapy. Proc. Am. Assoc. Cancer Res., 42: 261, 2001.
62. Britten, C. D., Rowinsky, E. K., Soignet, S., Patnaik, A., Yao, S. L., Deutsch, P., Lee, Y., Lobell, R. B., Mazina, K. E., McCrcery, H., Pezzuli, S., and Spriggs, D. A Phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin. Cancer Res., 7: 3894-3903, 2001.
63. Lobell, R. B., Liu, D., Buser, C. A., Davide, J. P., DePuy, E., Hamilton, K., Koblan, K. S., Lee, Y., Mosser, S., Motzel, S. L., Abbruzzese, J. L., Fuchs, C. S., Rowinsky, E. K., Rubin, E. H., Sharma, S., Deutsch, P. J., Mazina, K. E., Morrison, B. W., Wildonger, L., Yao, S. L., and Kohl, N. E. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol. Cancer Ther., 1: 747-758. 2002.
64. Lebowitz, P. F., and Prendergast, G. C. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene, 17: 1439-1445, 1998.
65. Zeng, Q., Si, X., Horstmann, H., Xu, Y., Hong, W., and Pallen, C. J. Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome. J. Biol. Chem., 275: 21444-21452, 2000.
66. Tamanoi, F., Kato-Stankiewicz, J., Jiang, C., Machado, I., and Thapar, N. Farnesylated proteins and cell cycle progression. J. Cell. Biochem. Suppl., 37 (Suppl.): 64-70, 2001.
67. Ellis, S., and Mellor, H. Regulation of endocytic traffic by rho family GTPases. Trends Cell Biol., 10: 85-88, 2000.
68. Adamson, P., Marshall, C. J., Hall, A., and Tilbrook, P. A. Post-translational modifications of p21rho proteins. J. Biol. Chem., 267: 20033-20038, 1992.
69. Fritz, G., Kaina, B., and Aktories, K. The Ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J. Biol. Chem., 270: 25172-25177, 1995.
70. Liu, A., Du, W., Liu, J. P., Jessell, T. M., and Prendergast, G. C. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol. Cell Biol., 20: 6105-6113, 2000.
71. Prendergast, G. C., and Oliff, A. Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects. Semin. Cancer Biol., 10: 443-452, 2000.
72. Du, W., Lebowitz, P. F., and Prendergast, G. C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell Biol., 19: 1831-1840, 1999.
73. Du, W., and Prendergast, G. C. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res., 59: 5492-5496, 1999.
74. Chen, Z., Sun, J., Pradines, A., Favre, G., Adnane, J., and Sebti, S. M. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J. Biol. Chem., 275: 17974-17978, 2000.
75. Ashar, H. R., James, L., Gray, K., Carr, D., Black, S., Armstrong, L., Bishop, W. R., and Kirschmeier, P. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J. Biol. Chem., 275: 30451-30457, 2000.
76. 2/M progression and degradation after mitosis. J. Cell Sci., 115: 3403-3414, 2002.
77. Crespo, N. C., Ohkanda, J., Yen, T. J., Hamilton, A. D., and Sebti, S. M. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J. Biol. Chem., 276: 16161-16167, 2001.
78. Crespo, N. C., Delarue, F., Ohkanda, J., Carrico, D., Hamilton, A. D., and Sebti, S. M. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death Differ., 9: 702-709, 2002.
79. 1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant. Mol. Microbiol., 41: 1339-1347, 2001.
80. Diamond, R. H., Cressman, D. E., Laz, T. M., Abrams, C. S., and Taub, R. PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol. Cell. Biol., 14: 3752-3762, 1994.
81. Cates, C. A., Michael, R. L., Stayrook, K. R., Harvey, K. A., Burke, Y. D., Randall, S. K., Crowell, P. L., and Crowell, D. N. Prenylation of oncogenic human PTP-(CAAX) protein tyrosine phosphatases. Cancer Lett., 110: 49-55, 1996.
82. Barrington, R. E., Subler, M. A., Rands, E., Omer, C. A., Miller, P. J., Hundley, J. E., Koester, S. K., Troyer, D. A., Bearss, D. J., Conner, M. W., Gibbs, J. B., Hamilton, K., Koblan, K. S., Mosser, S. D., O'Neill, T. J., Schaber, M. D., Senderak, E. T., Windle, J. J., Oliff, A., and Kohl, N. E. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol., 18: 85-92, 1998.
83. Moasser, M. M., Sepp-Lorenzino, L., Kohl, N. E., Oliff. A., Balog, A., Su, D. S., Danishefsky, S. J., and Rosen, N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA, 95: 1369-1374, 1998.
84. Suzuki, N., Urano, J., and Tamanoi, F. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc. Natl. Acad. Sci. USA, 95: 15356-15361, 1998.
85. Zhang, B., Prendergast, G. C., and Fenton, R. G. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res., 62: 450-458, 2002.
86. Barradas, M., Monjas, A., Diaz-Meco, M. T., Serrano, M., and Moscat, J. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. EMBO J., 18: 6362-6369, 1999.
87. Bredel, M., Pollack, I. F., Freund, J. M., Hamilton, A. D., and Sebti, S. M., Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth. Neurosurgery, 43: 124-131, 1998.
88. Jiang, K., Coppola, D., Crespo, N. C., Nicosia, S. V., Hamilton, A. D., Sebti, S. M., and Cheng, J. Q. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell. Biol., 20: 139-148, 2000.
89. Mangues, R., Corral, T., Kohl, N. E., Symmans, W. F., Lu, S., Malumbres, M., Gibbs, J. B., Oliff, A., and Pellicer, A. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res., 58: 1253-1259, 1998.
90. Prevost, G. P., Pradines, A., Viossat, I., Brezak, M. C., Miquel, K., Lonchampt, M. O., Kasprzyk, P., Favre, G., Pignol, B., Le Breton, C., Dong, J., and Morgan, B. Inhibition of human tumor cell growth in vitro and in vivo by a specific inhibitor of human farnesyltransferase: BIM-46068. Int. J. Cancer, 83: 283-287, 1999.
91. Garcia, A. M., Rowell, C., Ackermann, K., Kowalczyk, J. J., and Lewis, M. D. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J. Biol. Chem., 268: 18415-18418, 1993.
92. James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., and Marsters, J. C., Jr. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science (Wash. DC), 260: 1937-1942, 1993.
93. Graham, S. M., Cox, A. D., Drivas, G., Rush, M. G., D'Eustachio, P., and Der, C. J. Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation. Mol. Cell. Biol., 14: 4108-4115, 1994.
94. Graham, S. M., Vojtek, A. B., Huff, S. Y., Cox, A. D., Clark, G. J., Cooper, J. A., and Der, C. J. TC21 causes transformation by Raf-independent signaling pathways. Mol. Cell. Biol., 16: 6132-6140, 1996.
95. Carboni, J. M., Yan, N., Cox, A. D., Bustelo, X., Graham, S. M., Lynch, M. J., Weinmann, R., Seizinger, B. R., Der, C. J., Barbacid, M., et al. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation. Oncogene, 10: 1905-1913, 1995.
96. Adjei, A. A., Davis, J. N., Bruzek, L. M., Erlichman, C., and Kaufmann, S. H. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin. Cancer Res., 7: 1438-1445, 2001.
97. Shi, B., Yaremko, B., Hajian, G., Terracina, G., Bishop, W. R., Liu, M., and Nielsen, L. L. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother. Pharmacol., 46: 387-393, 2000.
98. Sun, J., Blaskovich, M. A., Knowles, D., Qian, Y., Ohkanda, J., Bailey, R. D., Hamilton, A. D., and Sebti, S. M. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyl-transferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res., 59: 4919-4926, 1999.
99. Liu, M., Bryant, M. S., Chen, J., Lee, S., Yaremko, B., Lipari, P., Malkowski, M., Ferrari, E., Nielsen, L., Prioli, N., Dell, J., Sinha, D., Syed, J., Korfmacher, W. A., Nomeir, A. A., Lin, C. C., Wang, L., Taveras, A. G., Doll, R. J., Njoroge, F. G., Mallams, A. K., Remiszewski, S., Catino, J. J., Girijavallabhan, V. M., and Bishop, W. R. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res., 58: 4947-4956, 1998.
100. FitzGerald, T. J., Daugherty, C., Kase, K., Rothstein, L. A., McKenna, M., and Greenberger, J. S., Activated human N-ras oncogene enhances x-irradiation repair of mammalian cells in vitro less effectively at low dose rate. Implications for increased therapeutic ratio of low dose rate irradiation. Am. J. Clin. Oncol. 8: 517-522, 1985.
101. Sklar, M. D., The ras oneogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science (Wash. DC), 239: 645-647, 1988.
102. McKenna, W. G., Weiss, M. C., Endlich, B., Ling, C. C., Bakanauskas, V. J., Kelsten, M. L., and Muschel, R. J. Synergistic effect of the v-myc oncogene with H-ras on radioresistance. Cancer Res., 50: 97-102, 1990.
103. McKenna, W. G., Weiss, M. C., Bakanauskas, V. J., Sandler, H., Kelsten, M. L., Biaglow, J., Tuttle, S. W., Endlich, B., Ling, C. C., and Muschel, R. J. The role of the H-ras oncogene in radiation resistance and metastasis. Int. J. Radiat. Oncol. Biol. Phys., 18: 849-859, 1990.
104. Hermens, A. F., and Bentvelzen, P. A. Influence of the H-ras oncogene on radiation responses of a rat rhabdomyosarcoma cell line. Cancer Res., 52: 3073-3082, 1992.
105. Bernhard, E. J., McKenna, W. G., Hamilton, A. D., Sebti, S. M., Qian, Y., Wu, J. M., and Muschel, R. J. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res., 58: 1754-1761, 1998.
106. Bernhard, E. J., Stanbridge, E. J., Gupta, S., Gupta, A. K., Soto, D., Bakanauskas, V. J., Cerniglia, G. J., Muschel, R. J., and McKenna, W. G. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res., 60: 6597-6600, 2000.
107. Cohen-Jonathan, E., Muschel, R. J., Gillies McKenna, W., Evans, S. M., Cerniglia, G., Mick, R., Kusewitt, D., Sebti, S. M., Hamilton, A. D., Cliff, A., Kohl, N., Gibbs, J. B., and Bernhard, E. J. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat. Res., 154: 125-132, 2000.
108. Evans, S. M., Joiner, B., Jenkins, W. T., Laughlin, K. M., Lord, E. M., and Koch, C. J. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br. J. Cancer, 72: 875-882, 1995.
109. 2 saturation measurements. Br. J. Cancer, 79: 464-471, 1999.
110. Vaupel, P., Thews, O., and Hoeckel, M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med. Oncol., 18: 243-259, 2001.
111. Kasid, U., Pfeifer, A., Brennan, T., Beckett, M., Weichselbaum, R. R., Dritschilo, A., and Mark, G. E. Effect of antisense e-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science (Wash. DC), 243: 1354-1356, 1989.
112. 2/M-phase arrest. Radiat. Res., 153: 371-383, 2000.
113. Gupta, A. K., Bernhard, E. J., Bakanauskas, V. J., Wu, J., Muschel, R. J., and McKenna, W. G. RAS-mediated radiation resistance is not linked to MAP kinase activation in two bladder carcinoma cell lines. Radiat. Res., 154: 64-72, 2000.
114. Gupta, A. K., Bakanauskas, V. J., Cerniglia, G. J., Cheng, Y., Bernhard, E. J., Muschel, R. J., and McKenna, W. G. The Ras radiation resistance pathway. Cancer Res., 61: 4278-4282, 2001.
115. Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J., Stolarov, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P., and Tonks, N. K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. USA, 95: 13513-13518, 1998.
116. Gupta, A. K., McKenna, W. G., Weber, C. N., Feldman, M. D., Goldsmith, J. D., Mick, R., Machtay, M., Rosenthal, D. I., Bakanauskas, V. J., Cerniglia, G. J., Bernhard, E. J., Weber, R. S., and Muschel, R. J. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin. Cancer Res., 8: 885-892, 2002.
117. Grana, T. M., Rusyn, E. V., Zhou, H., Sartor, C. I., and Cox, A. D. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res., 62: 4142-4150, 2002.
118. Harousseau, L-L., Stone, R., Thomas, X., Lancet, J., Arani, R., Thibault, A., and Rackoff, W. Interim results from a Phase 11 study of R115777 (Zamestra) in patients with relapsed and refractory acute myelogenous leukemia. Proc. Am. Soc. Clin. Oncol., 21: 1056, 2002.
119. Gotlib, J., Dugan, K., Katamneni, U., Sridhar, K., Wright, J., Thibault, A., Ryback, M. E., and Greenberg, P. L. Phase I/II study of farnesyltransferase inhibitor R 115777 (Zarnestra) in patients with myeloproliferative disorders (MPDs): preliminary results. Proc. Am. Soc. Clin. Oncol., 21: 14, 2002.
120. Johnston, S. R., Hickish, T., Houston, S., Ellis, P. A., Howes, A. J., and Thibault, A. Efficacy and tolerability of two dosing regimens of R115777 (Zarnestra), a farnesyl protein transferase inhibitor, in patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol., 21: 138, 2002.
121. Cloughesy, T. F., Kuhn, J., Wen, P., Chang, S. M., Schiff, D., Greenberg, H., Junck, L., Robins, I., DeAngelis, L. M., Yung, A., Groves, M., Fink, K., Abrey, L. E., Lieberman, F., Mehta, M. P., Raizer, J. J., Hess, K., and Prados, M. Phase II trial of R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED): a North American Brain Tumor Consortium (NABTC) report. Proc. Am. Soc. Clin. Oncol., 21: 317, 2002.
122. Adjei, A. A., Mauer, A., Marks, R., Hillman, S., Bruzek, L., M., Geyer, S., Hanson, L. J., Erlichman, C., Kaufmann, S. H., and Vokes, E. E. A Phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 21: 1156, 2002.
123. Heymach, J. V., De Porre, P. M., DeVore, R. F., III, Johnson, D. H., Khuri, F. R., Richards, H. M., Safran, H., Schlabach, L. L., Yunus, F., Jia, X., and Johnson, B. E. Phase II study of the farnesyl transferase inhibitor (FTI) R115777 (Zarnestra) in patients with relapsed small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol., 21: 1275, 2002.
124. Evans, T. L., Fidias, P., Skarin, A., Johnson, B., Moore, M., Pramanik, B., Aisner, J., Garcia, M., Morrison, B., Deutsch, P., Kenny, E., and Lynch, T. J., Jr. A Phase II study of efficacy and tolerability of the farnesyl-protein transferase inhibitor L-778,123 as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 21: 1861, 2002.
125. Hahn, S. M., Bernhard, E. J., Regine, W., Mohiuddin, M., Haller, D. G., Stevenson, J. P., Smith, D., Pramanik, B., Tepper, J., DeLaney, T. F., Kiel, K. D., Morrison, B., Deutsch, P., Muschel, R. J., and McKenna, W. G. A Phase 1 trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin. Cancer Res., 8: 1065-1072, 2002.
126. Cunningham, D., de Gramont, A., Scheithauer, W., Smakal, W., Humblet, Y., Kurteva, G., Iveson, T., Andre, T., Dostalova, J., Illes, A., Jia, X., and Palmer, P. Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra™) in advanced refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol., 21: 502, 2002.
127. Van Cutsem, E., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., Schoffski, P., Post, S., Neumann, H., Safran, H., Humblet, Y., van de Velde, H., Ma, Y., and Von Hoff, D. Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc. Am. Soc. Clin. Oncol., 21: 517, 2002.
128. Verslype, C., Van Steenbergen, W., Humblet, Y., Mars, H., De Vis, J., Palmer, P., Seifert, W., Bol, C., and Van Cutsem, E. Phase I trial of 5-FU/LV in combination with the farnesyltransferase inhibitor (FTI) R115777, Proc. Am. Soc. Clin. Oncol., 20: 681, 2001.
129. Patnik, A., Eckhardt, S., Itzbicka, E., Hidalgo, M., McCreery, H., Mori, M., Terada, K., Tolcher, A., Schwartz, L., Horak, L., Gentner, L., and Rowinsky, E. A Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with gemcitabine (gem). Proc. Am. Soc. Clin. Oncol., 19: 2a, 2000.
130. Adjei, A. A., Erlichman, C., Marks, R. S., Croghan, G. A., Sloan, J. A., Hanson, L. J., Reid, J. M., Atherton, P. J., Pitot, H. C., Alberts. S. R., Seifert, W. F., Thibault, A., and Kaufmann, S. H. A Phase I trial of the farnesyltransferase inhibitor R115777, in combination with gemcitabine and cisplatin in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol., 20: 320, 2001.
131. Liebes, L., Hochster, H., Speyer, J., Chachoua, A., Hamilton, A., Oratz, R., Pavlick, A., Sorich, J., Francois, A., and Muggia, F. Enhanced myelosuppression of topotecan when combined with the farnesyl transferase inhibitor, R115777: a Phase I and pharmacodynamic study. Proc. Am. Soc. Clin. Oncol., 20: 321, 2001.
132. Verweij, J., Kehrer, D. F. S., Planting, A. S. T., de Jonge, M. J. A., Eskens, F., Klaren, A., De Heus, G., Palmer, P. A., Bol, C. J., and Sparreboom, A. Phase I trial of irinotecan in combination with the farnesyl transferase inhibitor (FTI) R115777. Proc. Am. Soc. Clin. Oncol., 20: 319, 2001.
133. Piccart-Gebhart, M. J., Branle, F., de Valeriola, D., Dubuisson, M., Hennebert, P., Gil, T., Forget, F., Seifert, W. F., Thibault, A., Bol, C. J., and Awada. A. A Phase I clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + doectaxel: a promising combination in patients (PTS) with solid tumors. Proc. Am. Soc. Clin. Oncol., 20: 318. 2002.
134. Holden, S. N., Eckhardt, S. G., Fisher, S., Persky, M., Mikule, C., O'Bryant, C. L., Morrow, M., Richards, H., Rodriguez, S., Bol, C. J., and Cohen, R. A Phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) R115777 and capecitabine in patients (PTS) with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol., 20: 316, 2001.
135. Hurwitz, H., Amado, R., Prager, D., Hecht, J., Cohen, D., Conway, D., Kadib, L., Mayers, A., Calzetta, A., Statkevich, P., Cutler, D., and Rosen, L. Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancers. Proc. Am. Soc. Clin. Oncol., 19: 185a, 2000.
136. Pierson, A. S., Holden, S. N., Basche, M., O'Bryant, C., Zakneon, S., Statkevich, P., Zhu, Y., Mikule, C., Grolnic, S., Deem, C., Persky, M., Barrett, D., Morrow, M., and Eckhardt, S. G., A Phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) sarasar (lonafarnib, SCH66336). cisplatin (C), and gemcitabine (G) in patients (pts) with advanced solid tumors. Proc. Am. Soc. Clin. Oncol., 21: 365, 2002.
137. Khuri, F. R., Glisson, B. S., Meyers, M. L., Herbst, R. S., Thall, P. F., Munden, R. F., Bangert, S., Cascino, M., Blumenschein, G., Pisters, K., and Hong, W. K. Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: dose finding, pharmacokinetics, efficacy/safety. Proc. Am. Soc. Clin. Oncol., 19: 799, 2000.
138. Sprague, E., Vokes, E. E., Garland, L. L., McCabe, M., O'Neill, S., Cutler, D., Von Hoff, D., and Ratain, M. J. Phase I study of continuous lonafarnib plus paclitaxel and carboplatin in refractory or advanced solid tumors. Proc. Am. Soc. Clin. Oncol., 21: 1920, 2002.
139. Lipton, A., Ready, N., Bukowski, R. M., Zaknoen, S., Heck, K-A., Statkevich, P., and Zhu, Y. Phase I study of continuous oral lonafarnib plus weekly paclitaxel for advanced cancer. Proc. Am. Soc. Clin. Oncol. 21: 364, 2002.
140. Bailey, H. H., Mamocha, R., Arzoomanian, R., Alberti, D., Binger, K., Volkman, J., Feierabend, C., Ellingen, S., Black, S., Hampton, H., Cooper, M. Hott, T., and Wilding, G. Phase I Trial of weekly paclitaxel and BMS214662 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol., 20: 314, 2001.
141. Sharma, S., Britten, C., Spriggs, D., Rosen, N., Soignet, S., Pezzulli, S., Patnaik, A., Kher, U., Arena, C., Deutsch, P., Yao, S., and Rowinsky, E. A Phase I and PK study of farnesyl transferase inhibitor L-778,123 administered as a seven day continuous infusion in combination with paclitaxel. Proc. Am. Soc. Clin. Oncol., 19: 185a, 2000.
142. Voice, J. K., Klemke, R. L., Le, A., and Jackson, J. H. Four human ras homologs differ in their abilities to activate Raf-1. induce transformation, and stimulate cell motility. J. Biol. Chem., 274: 17164-17170, 1999.
143. Yan, J., Roy, S., Apolloni, A., Lane, A., and Hancock, J. F. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J. Biol. Chem., 273: 24052-24056, 1998.
144. Walsh, A. B., and Bar-Sagi, D. Differential activation of the Rac pathway by Ha-Ras and K-Ras. J. Biol. Chem., 276: 15609-15615, 2001.
145. Wolfman, J. C., and Wolfman, A. Endogenous c-N-Ras provides a steady-state anti-apoptotic signal. J. Biol. Chem., 275: 19315-19323, 2000.
146. McKenna, W. G., Bernhard, E. J., Markiewicz, D. A., Rudoltz, M. S., Maity, A., and Muschel, R. J. Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: influence of H-ras on the G2 delay. Oncogene. 12: 237-245, 1996.
147. Bos, J. L. Ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
148. Cohen, S. J., Ho, L., Ranganathan, S., Lewis, N., Rogatko, A., Weiner, L. M., Alpaugh, K., Abbruzzese, J. L., Beard, M., McLaughlin, S., Wright, J. J., Verhaeghe, T., Hudes, G. R., and Meropol, N. J. Phase 11 and pharmacodynamic trial of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. Proc. Am. Soc. Clin. Oncol., 21: 545, 2002.
149. MacDonald, J. S., Chansky, K., Whitehead, R., Wade, J., Giguere, J., and Abbruzzese, J. L. A Phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer. A Southwest Oncology Group (SWOG) study. Proc. Am. Soc. Clin. Oncol., 21: 548, 2002.